CA-EYENUK-INC
12.9.2019 09:07:08 CEST | Business Wire | Press release
Eyenuk Inc. , a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that the EyeArt® AI Eye Screening System was deployed successfully for Italy’s first national prevention and diagnosis campaign for retinal and diabetic maculopathy. A total of 2,200 patients were screened at 30 centers across Italy, with more than half chosen for EyeArt AI Eye Screening. The Month of Prevention of Diabetic Retinopathy and Maculopathy was sponsored by the Italian Ministry of Health, the city of Milan and the Italian Ophthalmology Society in collaboration with the Ambrosian Ophthalmic Center (CAMO), San Raffaele Hospital and Eyenuk.
In Italy, an estimated 3.2 million patients have diabetes. As many as 25% are estimated to be affected by diabetic retinopathy (DR),1 the main cause of vision impairment and blindness among working-age adults. DR occurs when high blood sugar levels lead to damage of the blood vessels in the light-sensitive tissue at the back of the eye, called the retina. Annual eye screening is recommended for people with diabetes since DR can progress silently without any perceptible symptoms or vision deterioration.
The EyeArt AI System uses artificial intelligence algorithms to autonomously analyze images of the eye taken with a retinal camera. Of the patients who underwent EyeArt AI Eye Screening, 214 patients were identified as having referable DR never diagnosed before; all were referred to eye care specialists to save their vision. The EyeArt AI System is the most extensively validated AI technology for autonomous detection of DR to date, tested in real-world settings on more than a half-million patient visits with more than 2 million images collected globally. In a prospective, pivotal clinical trial on more than 900 patients, the EyeArt System was shown to have 95.5% sensitivity and 86% specificity for detecting referable DR.
"Using the EyeArt AI System for our screening campaign was an extraordinary success. Nearly 17% of the patients screened had never received a complete diabetic eye exam, and another 8% hadn’t been screened in more than four years," says Dr. Lucio Buratto, scientific director of CAMO. “With the EyeArt AI System, we were able to examine thousands of patients in a fraction of the time that it would have otherwise taken. We can conclude that a prompt diagnosis and proper treatment could reduce 50-70% of the cases that show a severe visual impairment due to diabetes and DR. What’s more, early detection means the cost of health and social care will be significantly lower. We look forward to using the EyeArt AI System in future campaigns and in our clinics.”
The EyeArt AI System allows diabetes care providers to quickly and accurately identify patients with referable DR, without needing eye care expertise on-site, so at-risk patients can be immediately referred to an ophthalmologist for further evaluation and vision-saving treatment. The EyeArt AI System removes the biggest obstacles to annual DR screening and diagnosis: timely access to screening and patient compliance.
“We are proud to be part of the first national screening campaign for diabetic retinopathy and maculopathy in Italy,” says Kaushal Solanki, CEO of Eyenuk. “Giving eye care providers the power to quickly screen thousands of people is gratifying, and we look forward to participating in similar initiatives worldwide.”
Eyenuk will showcase its EyeArt AI Eye Screening System at the European Association for the Study of Diabetes (EASD) annual meeting (Booth #D.02) Sept. 16-20, 2019, in Barcelona, Spain.
VIDEO: Learn more about the EyeArt AI Eye Screening System for Diabetic Retinopathy from Dr. Buratto .
About the EyeArt AI Eye Screening System
The EyeArt AI Eye Screening System provides fully automated DR screening, including retinal imaging, DR grading on international standards and reporting on-site, in a single office visit during a diabetic patient’s regular exam. Once the patient’s fundus images have been captured and submitted to the EyeArt AI System, the DR screening results are available in a PDF report in less than 60 seconds.
About Eyenuk Inc.
Eyenuk Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk’s first product, the EyeArt AI Eye Screening System, is the most extensively validated AI technology for autonomous detection of DR. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease. Find Eyenuk online on its website , Twitter , Facebook , and LinkedIn .
The EyeArt System has CE marking and has been cleared for sales as a Class IIa medical device by the European Union and as a Class 2 medical device by Health Canada. In the U.S., the EyeArt System is limited to investigational use only.
EyeArt® is a registered trademark of Eyenuk Inc.
_________________________________
1
https://www.istat.it/en/archivio/202712
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005294/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Modon Partners With Montage Hotels & Resorts to Bring Ultra-Luxury Hospitality Brand to Egypt’s Ras El Hekma17.5.2026 13:53:00 CEST | Press release
Montage Ras El Hekma introduces the first branded residences for purchase at the Mediterranean destination, alongside the region’s first Montage resort Abu Dhabi-based Modon Holding and Montage Hotels & Resorts have announced Montage Ras El Hekma, which will introduce the first branded residences for purchase at Ras El Hekma on Egypt’s Mediterranean coast. This is the first Montage resort in Egypt – supporting the emerging city’s growth as a global hub for leisure, business and tourism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517167234/en/ Modon partners with Montage Hotels & Resorts to bring ultra-luxury hospitality brand to Egypt’s Ras El Hekma (Photo: AETOSWire) Montage Ras El Hekma will feature 200 guestrooms and suites, in addition to 96 Montage Residences, and will offer a curated mix of wellness and leisure amenities, including beachfront swimmable lagoons, a Spa Montage with 13 treatment rooms, and six dini
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Selects MEVION S250-FIT™ for Southern Italy’s First Proton Therapy Center17.5.2026 08:00:00 CEST | Press release
Compact, vault-integrated platform selected through a competitive European tender will bring proton therapy to patients across Southern Italy. Mevion Medical Systems, the global leader in compact proton therapy, today announced that it has been selected to deliver the MEVION S250-FIT Proton Therapy System™ to Istituto Nazionale Tumori IRCCS Fondazione G. Pascale in Naples. The award, made following a competitive European tender, will establish the first proton therapy center in Southern Italy, significantly expanding access to advanced radiation therapy for patients across the region and reducing the need for patients to travel long distances to northern Italy for care. Until now, proton therapy in Italy has only been available at centers located in Northern Italy, requiring patients from Southern Italy to travel significant distances for care. The Pascale project supports a broader strategy to establish Naples as a leading oncology hub and to improve healthcare equity across Italy. “T
TetraMem Announces 22nm Multi-Level RRAM Analog In-Memory Computing SoC Milestone16.5.2026 10:43:00 CEST | Press release
TetraMem Inc., a Silicon Valley–based semiconductor company developing analog in-memory computing (IMC) solutions, today announced the successful tape-out, manufacturing, and initial silicon validation of its MLX200 platform, a 22nm multi-level RRAM-based analog IMC system-on-chip (SoC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260516556464/en/ Photograph of the MLX200 chip with a five-cent coin for size reference The achievement marks a significant step toward the commercialization of analog computing architectures based on emerging non-volatile memory technologies, addressing the growing challenges of data movement, power consumption, and thermal constraints in modern AI systems. As AI workloads continue to scale, system performance is increasingly constrained by the cost of moving data between memory and compute units. Analog in-memory computing offers a fundamentally different approach by performing computation dir
STARTEEPO Invest Announces 5% Stake in Xerox Holdings Corporation15.5.2026 18:15:00 CEST | Press release
STARTEEPO Invest (“STARTEEPO”), an alternative investment fund focused on public equity opportunities, today announced that it has acquired a significant ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515594020/en/ As of the date of this release, STARTEEPO and its affiliates beneficially owns 6.6 million shares of Xerox (excluding options), representing approximately 5.05% of the Company’s outstanding common stock. STARTEEPO has filed a Schedule 13D with the U.S. Securities and Exchange Commission (the “SEC”) providing additional details regarding its investment. Investment Perspective STARTEEPO believes that Xerox represents an interesting investment opportunity supported by a combination of balance sheet initiatives, ongoing operational improvements, and its position within a changing and consolidating industry. In STARTEEPO’s view, the Company
NTT DATA Announces Intent to Acquire WinWire to Scale Enterprise AI Adoption and Accelerate Industry Transformation with Microsoft15.5.2026 16:00:00 CEST | Press release
Accelerates AI‑driven transformation through expanded agentic AI and data engineering capabilities that underpin NTT DATA’s AI strategy Adds 1,000 Azure engineers and AI specialists to scale cloud and AI delivery capabilities Advances NTT DATA’s North America leadership position, scaling industry aligned AI led innovation across its cloud services and Microsoft Business Unit Builds on NTT DATA’s position as the fastest-growing Microsoft GSI partner, accelerating co-innovation in enterprise AI NTT DATA, a global leader in AI, digital business and IT services, today announced it has signed a definitive agreement to acquire WinWire,an award-winning Microsoft partner specializing in Agentic AI, AI on Azure, data engineering and cloud-native development as foundational capabilities for enterprise AI. The acquisition strengthens NTT DATA’s position as a trusted partner to help organizations move beyond experimentation to operationalize AI at scale. The acquisition further advances NTT DATA’s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom